CP-47,497
Structural formula | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | |||||||||||||
Surname | CP-47,497 | ||||||||||||
other names |
( Z ) -3- [4- (1,1-Dimethylheptyl) -2-hydroxyphenyl] cyclohexanol |
||||||||||||
Molecular formula | C 21 H 34 O 2 | ||||||||||||
External identifiers / databases | |||||||||||||
|
|||||||||||||
Drug information | |||||||||||||
Drug class | |||||||||||||
Mechanism of action | |||||||||||||
properties | |||||||||||||
Molar mass | 318.49 g · mol -1 | ||||||||||||
Physical state |
firmly |
||||||||||||
Melting point |
109-110 ° C |
||||||||||||
safety instructions | |||||||||||||
|
|||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
CP 47,497 is a cannabinoid receptor CB 1 - agonist , which in the 1980s by the company Pfizer has been developed. The substance has analgesic effects. CP-47,497 is highly biologically active and has a dissociation constant of 2.1 nmoles.
Descendants
CP-47,497 has three analogues that are also regulated by narcotics law in Germany.
Short name | Surname | IUPAC name |
---|---|---|
CP-47,497 | ( cis -3- [4- (1,1-Dimethylheptyl) -2-hydroxyphenyl] -cyclohexanol) | 5- (1,1-Dimethylheptyl) -2 - [(1 RS , 3 SR ) -3-hydroxycyclohexyl] phenol |
CP-47,497-C6 homolog | ( cis -3- [4- (1,1-Dimethylhexyl) -2-hydroxyphenyl] -cyclohexanol) | 5- (1,1-Dimethylhexyl) -2 - [(1 RS , 3 SR ) -3-hydroxycyclohexyl] phenol |
CP-47,497-C8 homolog or cannabicyclohexanol | ( cis -3- [4- (1,1-Dimethyloctyl) -2-hydroxyphenyl] -cyclohexanol) | 5- (1,1-Dimethyloctyl) -2 - [(1 RS , 3 SR ) -3-hydroxycyclohexyl] phenol |
CP-47,497-C9 homolog | ( cis -3- [4- (1,1-Dimethylnonyl) -2-hydroxyphenyl] -cyclohexanol) | 5- (1,1-Dimethylnonyl) -2 - [(1 RS , 3 SR ) -3-hydroxycyclohexyl] phenol |
On January 19, 2009, employees of the University of Freiburg announced that u. a. "A chemically slightly modified form (analogue) of the synthetic cannabinoid CP-47,497" is one of the effective ingredients of the drug Spice .
Legal position
- Germany : With effect from January 22, 2009, CP-47,497 was classified in Germany as a marketable but not a prescription narcotic by entry in Annex II of the Narcotics Act (BtMG) .
- Switzerland : With the entry into force of the revised Narcotics Ordinance by Swissmedic on December 1, 2010, CP-47,497 was made subject to the Narcotics Act and was therefore illegal from that point on. Importation, possession, distribution etc. are punished according to the Narcotics Act.
Individual evidence
- ↑ LS Melvin, MR Johnson, CA Harbert, GM Milne, A. Weissman: A cannabinoid derived prototypical analgesic. In: J. Med. Chem. 27, 1984, pp. 67-71, doi: 10.1021 / jm00367a013 .
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
- ^ A. Weissman, GM Milne, LS Melvin Jr .: Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. In: Journal of Pharmacology and Experimental Therapeutics . tape 223 , no. 2 , November 1982, pp. 516-523 ( aspetjournals.org [accessed January 19, 2009]).
- ↑ JY Shim, WJ Welsh, AC Howlett: Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. In: Biopolymers . 71 (2), 2003, pp. 169-189. PMID 12767117 .
- ↑ Roger Pertwee: Cannabinoids. (= Handbook of Experimental Pharmacology. Vol. 168). Springer, 2005, ISBN 3-540-22565-X .
- ↑ PJ Little, DR Compton, MR Johnson, LS Melvin, BR Martin: Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. In: Journal of Pharmacology and Experimental Therapeutics . 247, 1988, pp. 1046-1051.
- ↑ Appendix II to the BtMG
- ↑ Main active ingredient of "Spice" identified. University of Freiburg.
- ↑ 22nd BtMÄndV of January 19, 2009 ( BGBl. I p. 49 ).
- ↑ Text of the Swissmedic Narcotics Ordinance, which came into force on December 1, 2010, as a PDF .
- ↑ Text of the Swiss Narcotics Act as PDF. Relevant criminal provisions: Art. 19 and following.